Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Blopress led sluggish Japanese market in 2008

This article was originally published in Scrip

Executive Summary

Takeda's Blopress (candesartan) was again the top-selling prescription drug in Japan last year, although growth for both it and the wider market was constrained by the regular reimbursement price cut in April. This averaged 5.2% and meant that the total market expanded by just 3% to ¥8,254.3 billion ($83.8 billion), compared with growth of around 5% in 2007, an "off year" for the biennial price revision.

You may also be interested in...



Otsuka Dermatitis Candidate Looks Good At Phase III

New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.

Japan Tirabrutinib Approval Breaks New BTK Ground In Lymphoma

Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.

Japan Enhertu Nod Another Boost For Daiichi's Oncology Hopes

Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.

Topics

Related Companies

UsernamePublicRestriction

Register

SC000719

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel